Prices are updated after-hours
  Health Technology 2021 - 04 - 30

nasdaq:MDVL MedAvail Holdings Inc.

MDVL 4 | $1.8 -0.56% 250K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (527.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (187.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,905,040
https://medavail.com
 Sec Filling | Patents | 15 employees


(US) MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.
optical  

add to watch list Paper trade email alert is off

nasdaq:AMYT Amryt Pharma plc

AMYT | $14.7 0.0% 2.4M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 940,255,350
http://amrytpharma.com
 Sec Filling | Patents | n/a employees


Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. It operates through the following segments: Commercial, Research and Development. The Commercial segment includes the financial results of the Group's two current commercial product lines, Imlan and Lojuxta. The Research and Development segment comprises the financial results of the Group’s two current research and development assets, AP101 and AP102. The company was founded by Joseph Amrit Wiley and Rory Peter Nealon on August 28, 2015 and is headquartered in Dublin, Ireland.
treatment  

Drugs
Juxtapid (lomitapide mesylate)
Myalept (metreleptin)

add to watch list Paper trade email alert is off

nasdaq:EAR Eargo, Inc.

EAR | $2.57 7.78% 200K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-52.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2984.13% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 53,385,286
http://www.eargo.com
 Sec Filling | Patents | 239 employees


Eargo, Inc. develops next generation hearing aids and headsets solutions. It offers Eargomax, a new chip for maximum audio fidelity and noise reduction and Eargoplus a superior hearing technology designed for first time hearing aid users. The company was founded by Florent Michel, Raphael Michel and Daniel Shen on November 12, 2010 and is headquartered in San Jose, CA.
audio   chip  

add to watch list Paper trade email alert is off

nasdaq:CEMI Chembio Diagnostics, Inc.

CEMI | $0.455 -5.25% 350K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (1.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (62.64% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 16,710,265
http://www.chembio.com
 Sec Filling | Patents | 324 employees


Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. The firm expanding its product portfolio based upon the proprietary Dual Path Platform, which uses a small drop of blood from the fingertip to provide cost-effective diagnostic results in approximately 15 minutes. Its products include human and veterinary diagnostics. The company was founded in 1985 and is headquartered in Hauppauge, NY.
infectious disease   diagnostics   veterinary  

add to watch list Paper trade email alert is off

nasdaq:CDAK Codiak BioSciences, Inc.

CDAK | $0.057 -55.99% -131.25% 0 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-0.9% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 2,099,289
http://www.codiakbio.com
 Sec Filling | Patents | 105 employees


(United States) Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.
diagnostics  

add to watch list Paper trade email alert is off

nasdaq:ADMP Adamis Pharmaceuticals Corporation

ADMP | $0.7751 0.86% 2.6% 120K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-88.5% 1y) (0.0% 2d) (0.9% 3d) (0.0% 7d) (20.14% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 7,254,264
http://www.adamispharmaceuticals.com
 Sec Filling | Patents | 171 employees


(US) Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. The company was founded in June 2006 and is headquartered in San Diego, CA.
respiratory   opioid  

add to watch list Paper trade email alert is off

nasdaq:ETTX Entasis Therapeutics Holdings Inc.

ETTX | $2.19 -0.46% 0.46% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-0.2% 1m) (0.0% 1y) (-0.2% 2d) (0.2% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-08-03
Market Cap: $ 104,795,396
http://www.entasistx.com
 Sec Filling | Patents | 47 employees


Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.
batteries   battery   msa   antibacterial   injection  

add to watch list Paper trade email alert is off

nasdaq:MTP Midatech Pharma PLC

MTP | $0.4703 -70.79% -73.69% 0 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-11.4% 1m) (0.0% 1y) (-11.4% 2d) (-11.4% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 3,260,999
http://midatechpharma.com/
 Sec Filling | Patents | n/a employees


Midatech Pharma Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in house programmes as well as partnered programmes. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is a innovative nanosaccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is a edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale ie i. chemotherapy - improved and targeted delivery of existing chemotherapeutic agents to tumor sites, as well as ii. immunotherapy - enhanced uptake of new immuno-moieties by immune cells that can then mount an immune attack against cancer cells. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
cancer   immunotherapy   t-cell   drug delivery   housing   ceiling  

add to watch list Paper trade email alert is off

nasdaq:NBRV Nabriva Therapeutics plc

NBRV | $1.42 1.39% 720K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-13.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3702.73% volume)
Earnings Calendar: 2023-08-03
Market Cap: $ 4,546,068
http://www.nabriva.com
 Sec Filling | Patents | 162 employees


(IE) Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, and CONTEPO. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
antibiotics   pleuromutilin antibiotic   antibacterial   injection  

add to watch list Paper trade email alert is off

nasdaq:HZNP Horizon Therapeutics Public Limited Company

HZNP | $116.3 0.03% 29M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (4.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (383.01% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 26,632,068,258
http://www.horizontherapeutics.com
 Sec Filling | Patents | 1200 employees


Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.


add to watch list Paper trade email alert is off

nasdaq:LJPC La Jolla Pharmaceutical Company

LJPC | $6.22 0.0% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (-0.2% 1m) (0.0% 1y) (0.0% 2d) (0.8% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 155,107,412
http://www.lajollapharmaceutical.com
 Sec Filling | Patents | 91 employees


(US) La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.
hormone   msa   treatment  

Drugs
Giapreza (angiotensin II)

add to watch list Paper trade email alert is off

nasdaq:RETA Reata Pharmaceuticals, Inc.

RETA | $172.36 0.02% 0.03% 0 twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (72.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (165.53% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 5,789,158,047
http://www.reatapharma.com
 Sec Filling | Patents | 220 employees


(US) Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
education  

add to watch list Paper trade email alert is off

nasdaq:EYES Second Sight Medical Products, Inc.

EYES | $4.14 -0.24% 3.14% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap:
http://www.secondsight.com
 Sec Filling | Patents | 112 employees


Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
china   prosthetics  

add to watch list Paper trade email alert is off

nasdaq:TCRR TCR2 Therapeutics Inc.

TCRR 4 | $1.48 3.38% 3.9M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (-12.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (906.93% volume)
Earnings Calendar: 2023-08-07
Market Cap: $ 58,107,383
http://www.tcr2.com
 Sec Filling | Patents | 83 employees


(US) TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. The firm offers cancer therapy, t-cell biology, immunology and molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of t-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.
cancer   immunotherapy   immunology   t-cell   ceiling  

add to watch list Paper trade email alert is off

nasdaq:PLXP PLx Pharma Inc.

PLXP | $0.087 -4.6% 50M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-04-17
Market Cap: $ 2,534,979
http://www.plxpharma.com
 Sec Filling | Patents | 12 employees


(US) PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.
gastrointestinal  

add to watch list Paper trade email alert is off

nasdaq:ONCY Oncolytics Biotech Inc.

ONCY | $1.045 -3.24% -3.35% 180K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (8.9% 1m) (-7.6% 1y) (0.0% 2d) (1.9% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2023-11-03
Market Cap: $ 78,813,658
http://www.oncolyticsbiotech.com
 Sec Filling | Patents | 23 employees


Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
pathogens   treatment  

add to watch list Paper trade email alert is off

nasdaq:ONTX Onconova Therapeutics, Inc.

ONTX | $0.9953 -5.61% 1.3M twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (20.5% 1m) (42.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-87.86% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 20,904,693
http://www.onconova.com
 Sec Filling | Patents | 19 employees


(US) Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
cancer   molecule drugs  

add to watch list Paper trade email alert is off

nasdaq:MITO Stealth BioTherapeutics Corp.

MITO | $0.32 0.25% twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1824.23% volume)
Earnings Calendar:
Market Cap: $ 23,536,789
http://www.stealthbt.com
 Sec Filling | Patents | 73 employees


(KY) Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Newton, MA.
mitochondrial dysfunction   parkinson   sbt-272   tdp-43  

add to watch list Paper trade email alert is off

nasdaq:AGEN Agenus Inc.

AGEN | $5.62 13.08% 510K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (796.1% 1m) (207.3% 1y) (0.0% 2d) (-21.1% 3d) (-23.5% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 2,354,330,799
http://www.agenusbio.com
 Sec Filling | Patents | 328 employees


(US) Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
cancer   infectious disease  

add to watch list Paper trade email alert is off

nasdaq:OPK Opko Health, Inc.

OPK | $1.235 0.41% 610K twitter stocktwits trandingview |
Health Technology
(0.0% 1d) (38.2% 1m) (-11.5% 1y) (0.0% 2d) (-1.6% 3d) (0.0% 7d) (-13.45% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 860,784,721
http://www.opko.com
 Sec Filling | Patents | 6096 employees


(US) OPKO Health, Inc. engages in the provision of healthcare services. It operates through the following segments: Diagnostics, Pharmaceuticals, and Corporate. The Diagnostics segment include clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes comprises pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
israel   diagnostics  

add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlist
Gainers vs Losers
74% 26%

Top 10 Gainers
AGBA | News | $1.27 217.5% 120M twitter stocktwits trandingview |
Finance
EGOX | $0.054 50.0% 290M twitter stocktwits trandingview |

INDO | $5.43 33.09% 10M twitter stocktwits trandingview |
Energy Minerals
NVFY | $2.71 28.44% 31M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.86 28.28% 29M twitter stocktwits trandingview |
Commercial Services
BSFC | $0.0822 27.64% 75M twitter stocktwits trandingview |
Manufacturing
RWOD | $10.08 26.05% 5.6M twitter stocktwits trandingview |
n/a
CHRO | $1.53 24.9% 100K twitter stocktwits trandingview |
n/a
HUSA 4 | $2.07 23.95% 2.1M twitter stocktwits trandingview |
Energy Minerals
INSG | $2.98 23.14% 190K twitter stocktwits trandingview |
Electronic Technology
Last 48 Hours Insiders Buying
CLSD | $1.42 7.58% 130K twitter stocktwits trandingview |
Health Technology
 | 14:00
CDZI P 25000 | $2.25 100K twitter stocktwits trandingview |
Utilities
 | 14:00
ETST P 39000 | $0.068 43K twitter stocktwits trandingview |
Manufacturing
 | 13:30
FNLC P 1275 | $22.62 2.08% 8K twitter stocktwits trandingview |
Finance
 | 12:30
ADMQ | $0.0532 480K twitter stocktwits trandingview |
| 10:30
AXR P 2400 | $21.02 -5.19% 3.5K twitter stocktwits trandingview |
Finance
 | 21:00
QCRH P 118 | $56.48 1.93% 15K twitter stocktwits trandingview |
Finance
 | 18:01
VUZI P 7500 | $1.26 230K twitter stocktwits trandingview |
Electronic Technology
 | 18:00
RMCF | $3.57 0.56% 7.9K twitter stocktwits trandingview |
Consumer Non-Durables
 | 20:10
12 months watchlist earnings calendar